Vibha Ravi
Senior Editor, Citeline - Scrip, Pink Sheet. Tweets on pharma, health, environment, other topics of interest to those who read beyond headlines, social media
Articles
-
2 weeks ago |
insights.citeline.com | Vibha Ravi
Aragen’s CEO Says NIH Funding Cut Means Less R&D Money, And Tariffs Would Add To Woes Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an interview. Aragen CEO Manni Kantipudi discussed US tariffs, manufacturing shifts, regulation and other issues.
-
2 weeks ago |
insights.citeline.com | Vibha Ravi
NIH Funding Cuts Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO IPR Challenges In India Being Addressed Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs Aragen CEO Manni Kantipudi Talks About US Tariffs,...
-
3 weeks ago |
insights.citeline.com | Vibha Ravi
Enzene To Prepone US Capacity Addition Amid Tariff TalkExemptions Possible For IndiaEnzene Biosciences is likely to front-load capacity at its new US facility amid an onshoring focus, CEO Himanshu Gadgil tells Scrip. Possible US tariff exemption for Indian pharma products, impact of higher steel and aluminum tariffs on US manufacturing and a change in the company’s biosimilars strategy are discussed in this wide-ranging interview Himanshu Gadgil, CEO, Enzene Biosciences (Enzene Biosciences Ltd)
-
3 weeks ago |
insights.citeline.com | Lisa Takagi |Joseph Haas |Anju Ghangurde |Vibha Ravi
Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding PlatformPlus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
-
1 month ago |
insights.citeline.com | Vibha Ravi
Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India? US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth Cell And Gene Therapy Is Picking Up Pace In India (Shutterstock)
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 673
- Tweets
- 4K
- DMs Open
- Yes
How to apply for the Global Generics & Biosimilars Award from Generics Bulletin, Citeline - @DaveGenerics shares all the details to nominate, sponsor and attend #awards #Citeline #pharmaceutical @Citeline https://t.co/tZp8019MNl
Taxes, Not Tariffs, Influence US Manufacturing, J&J CEO Says #Tariffs #Trump #Pharmaceuticals #business https://t.co/T2YWaf6Qd6
Pharma deals across the world: A round up brought by my colleague Joseph Haas, who painstakingly puts them together @PharmaScrip #deals #MergersAndAcquisitions #pharmanews https://t.co/nN7sHOLeC9